.

Biomarin Pharmaceutical reported $123.13M in Cost of Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.67M 0.28M
Acorda Therapeutics ACOR:US $ 8.8M 2.83M
Agios Pharmaceuticals AGIO:US $ 0.44M 0.1M
Alnylam Pharmaceuticals ALNY:US $ 40.81M 5.18M
Amgen AMGN:US $ 1510M 51M
Bayer BAYN:GR € 5680M 504M
Biogen BIIB:US $ 484M 269.9M
Biomarin Pharmaceutical BMRN:US $ 123.13M 6.16M
Bluebird Bio BLUE:US $ 1.74M 6.56M
Gilead Sciences GILD:US $ 1442M 18M
Insmed INSM:US $ 16.4M 4.2M
Intercept Pharmaceuticals ICPT:US $ 0.31M 0.45M
IONIS PHARMACEUT IONS:US $ 4.74M 0.57M
Moderna Inc MRNA:US 1.38B 364M
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Ptc Therapeutics PTCT:US $ 9.64M 0.5M
Puma Biotechnology PBYI:US $ 14.92M 4.07M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Sarepta Therapeutics SRPT:US $ 37.8M 6.35M
Seattle Genetics SGEN:US $ 106.1M 18.47M
Ultragenyx Pharmaceutical RARE:US $ 8.27M 2.17M
United Therapeutics UTHR:US $ 29.7M 3.8M
Vertex Pharmaceuticals VRTX:US $ 261.8M 16M
YTE INCY:US $ 45.24M 8.02M